{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:13:20Z","timestamp":1789726400761,"version":"4.0.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.mcna.2006.06.008","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T09:28:20Z","timestamp":1168421300000},"page":"1223-1255","source":"Crossref","is-referenced-by-count":55,"title":["Antibiotic Drug Interactions"],"prefix":"10.1016","volume":"90","author":[{"given":"Manjunath P.","family":"Pai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Momary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Rodvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2006.06.008_bib1","series-title":"Drug interactions in infectious diseases","first-page":"83","article-title":"Drug interactions: regulatory perspective","author":"Reynolds","year":"2005"},{"issue":"17","key":"10.1016\/j.mcna.2006.06.008_bib2","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","article-title":"Timing of new black box warnings and withdrawals for prescription medications","volume":"287","author":"Lasser","year":"2002","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.mcna.2006.06.008_bib3","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1086\/379830","article-title":"Safety and efficacy evaluation of pleconaril for treatment of the common cold","volume":"37","author":"Fleischer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mcna.2006.06.008_bib4","series-title":"Drug interactions in infectious diseases","year":"2005"},{"key":"10.1016\/j.mcna.2006.06.008_bib5","series-title":"Hansten and Horn's Managing clinically important drug interactions 2005","author":"Hansten","year":"2005"},{"key":"10.1016\/j.mcna.2006.06.008_bib6","series-title":"Drug interaction facts 2006: the authority on drug interactions","author":"Tatro","year":"2006"},{"key":"10.1016\/j.mcna.2006.06.008_bib7","series-title":"Stockley's drug interactions","author":"Baxter","year":"2005"},{"key":"10.1016\/j.mcna.2006.06.008_bib8","series-title":"Drug interactions in infectious diseases","first-page":"41","article-title":"Mechanisms of drug interactions II: transport proteins","author":"Penzak","year":"2005"},{"issue":"2","key":"10.1016\/j.mcna.2006.06.008_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2125.1994.tb04251.x","article-title":"Plasma protein binding displacement interactions: why are they still regarded as clinically important?","volume":"37","author":"Rolan","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.mcna.2006.06.008_bib10","series-title":"Drug interactions in infectious diseases","first-page":"255","article-title":"\u03b2-lactam antibiotics","author":"Neuhauser","year":"2005"},{"issue":"4","key":"10.1016\/j.mcna.2006.06.008_bib11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0749-0704(05)70367-5","article-title":"Antibiotic-induced convulsions","volume":"13","author":"Wallace","year":"1997","journal-title":"Crit Care Clin"},{"issue":"4","key":"10.1016\/j.mcna.2006.06.008_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/archinte.1951.03810100073006","article-title":"Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin: studies including observations on an apparent antagonism between penicillin and aureomycin","volume":"88","author":"Lepper","year":"1951","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1016\/j.mcna.2006.06.008_bib13","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00134-005-2695-0","article-title":"Pharmacokinetic interaction between valproic acid and meropenem","volume":"31","author":"Clause","year":"2005","journal-title":"Intensive Care Med"},{"issue":"6","key":"10.1016\/j.mcna.2006.06.008_bib14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1067\/mjd.2002.120448","article-title":"Oral contraceptive efficacy and antibiotic interaction: a myth debunked","volume":"46","author":"Archer","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.mcna.2006.06.008_bib15","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.mcna.2006.06.008_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1345\/aph.19138","article-title":"Macrolide drug interactions: an update","volume":"34","author":"Pai","year":"2000","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.mcna.2006.06.008_bib17","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2165\/00003088-200544090-00003","article-title":"Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial","volume":"44","author":"Shi","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.mcna.2006.06.008_bib18","series-title":"Antimicrobial agents: antibacterials and antifungals","first-page":"1320","article-title":"Drug interactions during anti-infective treatments","author":"Petitjean","year":"2005"},{"issue":"11","key":"10.1016\/j.mcna.2006.06.008_bib19","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa040582","article-title":"Oral erythromycin and the risk of sudden death from cardiac causes","volume":"351","author":"Ray","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mcna.2006.06.008_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1098-3597(05)80048-1","article-title":"The efficacy and safety of PDE5 inhibitors","volume":"7","author":"Rashid","year":"2005","journal-title":"Clin Cornerstone"},{"issue":"1","key":"10.1016\/j.mcna.2006.06.008_bib21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2125.2003.01824.x","article-title":"Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction","volume":"56","author":"Rengelshausen","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"13","key":"10.1016\/j.mcna.2006.06.008_bib22","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jama.289.13.1652","article-title":"Drug\u2013drug interactions among elderly patients hospitalized for drug toxicity","volume":"289","author":"Juurlink","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mcna.2006.06.008_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/431592","article-title":"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study","volume":"41","author":"Hung","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"4594","key":"10.1016\/j.mcna.2006.06.008_bib24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1126\/science.6836275","article-title":"Digoxin-inactivating bacteria: identification in human gut flora","volume":"220","author":"Saha","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.mcna.2006.06.008_bib25","series-title":"Drug interactions in infectious diseases","first-page":"215","article-title":"Quinolones","author":"Guay","year":"2005"},{"issue":"3","key":"10.1016\/j.mcna.2006.06.008_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2006.01.003","article-title":"Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate","volume":"5","author":"Pai","year":"2006","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.mcna.2006.06.008_bib27","series-title":"Product information: Cipro, ciprofloxacin hydrochloride tablets, ciprofloxacin oral suspension","year":"2005"},{"key":"10.1016\/j.mcna.2006.06.008_bib28","series-title":"Product information: Levaquin, levofloxacin","year":"2005"},{"key":"10.1016\/j.mcna.2006.06.008_bib29","series-title":"Product information: Tequin, gatifloxacin","year":"2006"},{"issue":"13","key":"10.1016\/j.mcna.2006.06.008_bib30","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1056\/NEJMoa055191","article-title":"Outpatient gatifloxacin therapy and dysglycemia in older adults","volume":"354","author":"Park-Wyllie","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2006.06.008_bib31","series-title":"Product information: Avelox, moxifloxacin","year":"2005"},{"key":"10.1016\/j.mcna.2006.06.008_bib32","series-title":"Product information: Factive, gemifloxacin mesylate","year":"2004"},{"key":"10.1016\/j.mcna.2006.06.008_bib33","series-title":"Drug interactions in infectious diseases","first-page":"339","article-title":"Miscellaneous antibiotics","author":"Susla","year":"2005"},{"issue":"7","key":"10.1016\/j.mcna.2006.06.008_bib34","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mcna.2006.06.008_bib35","series-title":"Therapeutic drug monitoring","first-page":"587","article-title":"Vancomycin","author":"Rodvold","year":"1995"},{"issue":"11","key":"10.1016\/j.mcna.2006.06.008_bib36","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/ajhp\/62.11.1145","article-title":"Daptomycin: a novel cyclic lipopeptide antimicrobial","volume":"62","author":"Schriever","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.mcna.2006.06.008_bib37","series-title":"Product information: Zyvox, linezolid","year":"2005"},{"issue":"5","key":"10.1016\/j.mcna.2006.06.008_bib38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/00912700122010302","article-title":"Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr","volume":"41","author":"Hendershot","year":"2001","journal-title":"J Clin Pharmacol"},{"issue":"Suppl A","key":"10.1016\/j.mcna.2006.06.008_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/44.suppl_1.37","article-title":"Safety and tolerability of quinupristin\/dalfopristin: administration guidelines","volume":"44","author":"Rubinstein","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mcna.2006.06.008_bib40","series-title":"Product information: Tygacil, tigecycline","year":"2005"},{"issue":"1","key":"10.1016\/j.mcna.2006.06.008_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/infdis\/167.1.173","article-title":"Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring","volume":"167","author":"Betino","year":"1993","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.mcna.2006.06.008_bib42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000180735","article-title":"Renal failure following gentamicin in combination with clindamycin","volume":"17","author":"Butkus","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.mcna.2006.06.008_bib43","series-title":"Drug interactions in infectious diseases","first-page":"383","article-title":"Drug\u2013food interactions","author":"Harris","year":"2005"},{"issue":"11","key":"10.1016\/j.mcna.2006.06.008_bib44","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1128\/AAC.47.11.3464-3469.2003","article-title":"Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes","volume":"47","author":"Park","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.mcna.2006.06.008_bib45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/dmd.30.6.631","article-title":"Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively","volume":"30","author":"Wen","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.mcna.2006.06.008_bib46","series-title":"Drug interactions in infectious diseases","first-page":"137","article-title":"Drugs for HIV-related opportunistic infections","author":"Tseng","year":"2005"},{"issue":"1","key":"10.1016\/j.mcna.2006.06.008_bib47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1124\/dmd.30.1.13","article-title":"The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion: correlation of in vivo and in vitro studies","volume":"30","author":"Hill","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2006.06.008_bib48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-199936001-00005","article-title":"The low potential for drug interactions with zanamivir","volume":"36","author":"Daniel","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.mcna.2006.06.008_bib49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00002018-200225020-00005","article-title":"Clinically significant interactions with drugs used in the treatment of tuberculosis","volume":"25","author":"Yew","year":"2002","journal-title":"Drug Saf"},{"issue":"9","key":"10.1016\/j.mcna.2006.06.008_bib50","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.mcna.2006.06.008_bib51","series-title":"Drug interactions in infectious diseases","first-page":"191","article-title":"Drugs for tuberculosis","author":"Namdar","year":"2005"},{"issue":"9","key":"10.1016\/j.mcna.2006.06.008_bib52","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/jnci\/86.9.712","article-title":"Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California","volume":"86","author":"Yu","year":"1994","journal-title":"J Natl Cancer Inst"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712506000654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712506000654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T12:51:20Z","timestamp":1556023880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712506000654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0025712506000654"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2006.06.008","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}